BiOPartnering Early Bird Registration – Only 2 Days Left

With just two days remaining to claim early bird access for BiOPartnering at BIOCHINA 2026, global biopharma leaders are already confirming their participation. Companies such as Bayer, Pfizer, Eli Lilly, Novartis, BMS, Hikma, and Dr. Reddy’s will send dedicated teams to actively source biologics, innovative drugs, and enabling technologies from Chinese companies.

BiOPartnering offers participants the opportunity to pre-schedule 1-on-1 meetings with C-level executives and business development decision-makers, ensuring every conversation is purposeful and results-oriented. Attendees can explore partnership opportunities, discuss licensing deals, or identify potential investors in targeted sessions. This is a unique chance to present projects directly to global pharma leaders, understand their R&D priorities, and accelerate business growth in both Chinese and international markets.

Beyond one-on-one meetings, BiOPartnering provides a focused networking environment connecting innovators, solution providers, and CDMOs. The platform is designed to maximize on-site efficiency, facilitating meaningful collaborations across the biopharma value chain and supporting strategic sourcing, licensing, and co-development initiatives.

Early Bird Advantage:

Secure your spot now to lock priority meeting slots and save $150 on registration. Early registration ensures you connect with the right partners before slots fill.

Register now: https://u.morebio.cn/MnEjmeQF

Learn more: https://www.biocn.cn/en/en.html

BiOPartnering at BIOCHINA2026 is where real deals, licensing agreements, and strategic partnerships happen—don’t miss your chance to be part of it.